Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.

@article{Attia2008PhaseIS,
  title={Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.},
  author={Steven Attia and Anne M. Traynor and KyungMann Kim and Joseph J Merchant and Tien H. Hoang and Harish G. Ahuja and Peter A Beatty and Richard M. Hansen and Gregory A Masters and Kurt R. Oettel and Gary R. Shapiro and Martha Moon Larson and Marilyn L Larson and Joan Hoff Schiller},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2008},
  volume={3 9},
  pages={1018-25}
}
INTRODUCTION Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC). Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents together as palliative treatment for older patients with advanced NSCLC. METHODS Chemotherapy-naive patients >/=70-years-old with stage IIIB-IV NSCLC and a performance status (PS) </=2 were eligible. Primary endpoints were the maximum tolerated dose (phase I) and time-to-progression… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
0 Extracted Citations
0 Extracted References
Similar Papers

Similar Papers

Loading similar papers…